A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes? Read more about A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis Read more about Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Efficacy and Safety of Grass-SPIRE Registration Study Read more about Efficacy and Safety of Grass-SPIRE Registration Study
Adjustable Balloons for Weight Loss: A Higher Yield of Responders Compared With Non-Adjustable Balloons Read more about Adjustable Balloons for Weight Loss: A Higher Yield of Responders Compared With Non-Adjustable Balloons
CTL019 Out of Specification MAP for ALL or DLBCL Patients Read more about CTL019 Out of Specification MAP for ALL or DLBCL Patients
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Read more about PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC Read more about The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Read more about Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer Read more about Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) Read more about To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)